TLR9 agonist CMP-001-pembrolizumab combination shows early efficacy for metastatic melanoma resistant to anti-PD-1

A combination of CMP-001, an intratumoral Toll-like receptor 9 (TLR9) agonist, and pembrolizumab (Keytruda), tested in patients with metastatic melanoma resistant to PD-1 checkpoint inhibition, was well tolerated and had clinical activity according to ...